Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-06-12
Target enrollment:
Participant gender:
Summary
To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective
response rate and other measures of efficacy for patients treated with panitumumab in
combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin
(FOLFIRI) as first-line therapy for metastatic colorectal cancer (mCRC).